The Globoid Cell Leukodystrophy (Krabbe Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Globoid Cell Leukodystrophy (Krabbe Disease). Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued products.

GlobalData tracks 14 drugs in development for Globoid Cell Leukodystrophy (Krabbe Disease) by 12 companies/universities/institutes. The top development phase for Globoid Cell Leukodystrophy (Krabbe Disease) is discovery with seven drugs in that stage. The Globoid Cell Leukodystrophy (Krabbe Disease) pipeline has 12 drugs in development by companies and two by universities/ institutes. Some of the companies in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products market are: M6P Therapeutics, Polaryx Therapeutics and Vascumab.

The key targets in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products market include Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46), Peroxisome Proliferator Activated Receptor Alpha (Nuclear Receptor Subfamily 1 Group C Member 1 or NR1C1 or PPARA), and Retinoic Acid Receptor RXR Alpha (Nuclear Receptor Subfamily 2 Group B Member 1 or Retinoid X Receptor Alpha or NR2B1 or RXRA).

The key mechanisms of action in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline product include Galactocerebrosidase (Galactosylceramidase or Galcerase or Galactocerebroside Beta Galactosidase or Galactosylceramide Beta Galactosidase or GALC or EC 3.2.1.46) Replacement with three drugs in Preclinical. The Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products include three routes of administration with the top ROA being Oral and seven key molecule types in the Globoid Cell Leukodystrophy (Krabbe Disease) pipeline products market including Small Molecule, and Gene Therapy.

Globoid Cell Leukodystrophy (Krabbe Disease) overview

Krabbe disease, also called globoid cell leukodystrophy, is a degenerative disorder caused by a deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, muscle spasms, loss of head control, vomiting, fever, irritability, and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsants, muscle relaxers) and providing supportive care.

For a complete picture of Globoid Cell Leukodystrophy (Krabbe Disease)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.